Cardiovascular risk of non-steroidal antiinflammatory drugs

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10376159" target="_blank" >RIV/00216208:11130/18:10376159 - isvavai.cz</a>
Result on the web
<a href="https://www.prolekare.cz/casopisy/vnitrni-lekarstvi/2018-3/kardiovaskularni-riziko-nesteroidnich-antirevmatik-63583?hl=en" target="_blank" >https://www.prolekare.cz/casopisy/vnitrni-lekarstvi/2018-3/kardiovaskularni-riziko-nesteroidnich-antirevmatik-63583?hl=en</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Cardiovascular risk of non-steroidal antiinflammatory drugs
Original language description
Non-steroidal anti-inflammatory drugs (NSAIDs) belong to the most widely used drugs. Results of recent large meta-analyses have shown that the cardiovascular risk of NSAIDs is more serious than originally believed and is not associated exclusively with coxibs; it is also increased when using so called traditional NSAIDs. Data obtained to date show the safest drugs of this class in terms of cardiovascular risk are naproxen and ibuprofen at low doses. The position of naproxen as the safest NSAID has been challenged by some more recent findings. The authors examine some results of meta-analyses and conclusions of regulatory agencies.
Czech name
—
Czech description
—

Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)